Trials / Not Yet Recruiting
Not Yet RecruitingNCT06654947
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib+Toripalimab+GEMOX | Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W） |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2024-10-23
- Last updated
- 2024-12-16
Source: ClinicalTrials.gov record NCT06654947. Inclusion in this directory is not an endorsement.